News

Use of the drug Soliris (eculizumab) effectively treated atypical hemolytic uremic syndrome (aHUS) in a pregnant woman in her 30s who developed the rare disease after having placental abruption, which occurs when the placenta separates from the inner wall of the uterus before birth. Her case was described…

At the onset of atypical hemolytic uremic syndrome (aHUS), patients are already showing signs of severe kidney injury, regardless of the specific triggers or disease-related clinical conditions they might also harbor, a registry study has found. Cancer, pregnancy, and acute infections were identified as the most common triggers before…

Soliris (eculizumab) was used to effectively treat atypical hemolytic uremic syndrome (aHUS) in a young woman with systemic lupus erythematosus (SLE), another autoimmune condition, a case report shows. The therapy was safely discontinued without causing an aHUS relapse, while immunosuppressant treatments for SLE were maintained. This “case highlights…

A 78-year-old woman developed atypical hemolytic uremic syndrome (aHUS) and acute kidney failure after contracting an infection with SARS-CoV-2, the virus that causes COVID-19, doctors wrote in a case study. Diffuse alveolar hemorrhage, a condition characterized by bleeding from the lung’s alveoli, or the tiny air sacs where gas…

In a young girl, thrombotic microangiopathy — a group of disorders, including atypical hemolytic uremic syndrome (aHUS), that are marked by organ damage caused by the formation of blood clots inside small blood vessels — occurred secondary to a sudden spike in blood pressure. Because the opposite is more…

A woman in her early 30s who developed pregnancy-associated atypical hemolytic-uremic syndrome (aHUS) after the birth of her baby saw her kidney function recover after being treated with Ultomiris (ravulizumab-cwvz), according to a case report. Clinicians diagnosed the rare condition a week after her first symptoms — which…

A rare mutation in the CFI gene affects the risk and clinical severity of various forms of hemolytic uremic syndrome (HUS), including atypical HUS (aHUS), according to a recent study. The study, “Hot Spot of Complement Factor I Rare Variant p.Ile357Met in Patients With Hemolytic Uremic Syndrome,” was published…

Soliris (eculizumab) appears to be more effective in atypical hemolytic uremic syndrome (aHUS) patients with complement abnormalities, than in those whose disease was triggered by other underlying conditions, a 20-year retrospective analysis has found. The risk of disease relapse over the course of five years was 40% higher…

The case of a 49-year-old man with atypical hemolytic uremic syndrome (aHUS) that manifested after he developed pancreatitis was described in a recent report. Genetic testing showed the man had a mutation in the MCP gene, a known risk factor for aHUS. The fact that he hadn’t had any…

Soliris (eculizumab) and hemodialysis improved kidney function in a man with end-stage kidney disease who was diagnosed with atypical hemolytic uremic syndrome (aHUS) after a kidney transplant, according to a case study from South Korea. The report “emphasizes the importance of primary kidney disease evaluation and careful monitoring”…